IQVIA Holdings Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ari Bousbib
- Full Time Employees
- 94,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2400 Ellis Road Durham NC United States of America 27703
- IPO Date
- May 9, 2013
- CIK
- 0001478242
- Website
- iqvia.com
- Similar Companies
- Business
- IQVIA Holdings Inc operates as a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries. The company offers a comprehensive portfolio including clinical trial services; commercial insights; healthcare intelligence; real-world evidence generation; and advanced data analytics powered by IQVIA Connected Intelligence™, Healthcare-grade AI™, and big data resources. Its technology solutions encompass software platforms for orchestrated customer engagement, data management, and commercial orchestration, supported by partnerships with leading technology providers such as NVIDIA and Veeva Systems. IQVIA's service offerings span drug development, regulatory consulting, market access, and patient centricity solutions, targeting pharmaceutical, biotechnology, and medical device companies worldwide. Headquartered in Durham, North Carolina, and founded through the 2016 merger of Quintiles and IMS Health, IQVIA operates in more than 100 countries with approximately 88,000 employees. Recent company developments include a strategic partnership with NVIDIA to integrate generative and agentic AI within clinical research workflows, accelerating innovation and efficiency in drug development. IQVIA also expanded a clinical and commercial collaboration with Veeva Technologies to enhance interoperability and deliver streamlined solutions for customers in clinical development and commercialization. In 2024 and 2025, IQVIA advanced its healthcare data analytics capabilities through acquisitions of healthcare technology firms, reinforcing its technology portfolio and enabling broader service offerings. Additionally, the company continues to support pharmaceutical product launches globally, tracking and analyzing launch excellence to optimize commercial success across multiple therapeutic areas. IQVIA's ongoing investments in AI and integrated technology ecosystems position it at the forefront of healthcare intelligence and life sciences services innovation.
Company News
IQVIA Selects Veeva Clinical Operations Applications
IQVIA Selects Veeva Clinical Operations Applications
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity
Rep. Kevin Hern Unloads Shares of Honeywell International Inc. (NASDAQ:HON)
Crane (NYSE:CR) Stock Sold Off by Rep. Kevin Hern
Walmart (NASDAQ:WMT) Shares Unloaded by Rep. Kevin Hern
Colgate-Palmolive (NYSE:CL) Stock Sale Revealed by Rep. Kevin Hern
Novo Nordisk A/S (NYSE:NVO) Stock Sold Off by Rep. Kevin Hern
Danaher (NYSE:DHR) Stock Unloaded by Rep. Kevin Hern
Rep. Kevin Hern Sells Shares of Devon Energy Corporation (NYSE:DVN)
Rep. Kevin Hern Sells Shares of ONEOK, Inc. (NYSE:OKE)
Pembina Pipeline (NYSE:PBA) Stock Sold by Rep. Kevin Hern
Rep. Kevin Hern Purchases Shares of CocaCola Company (The) (NYSE:KO)
Novartis (NYSE:NVS) Stock Sold by Rep. Kevin Hern
PTC (NASDAQ:PTC) Stock Sale Disclosed by Rep. Kevin Hern
CSX (NASDAQ:CSX) Shares Sold by Rep. Kevin Hern
Progress Software (NASDAQ:PRGS) Stock Sold Off by Rep. Kevin Hern